A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

R. F. Kefford, N. P B Thomas, P. G. Corrie, C. Palmer, E. Abdi, D. Kotasek, J. Beith, M. Ranson, P. Mortimer, A. J. Watson, G. P. Margison, M. R. Middleton

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Lomeguatrib, an O 6 -methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated with lomeguatrib 40 mg, b.i.d. for 10 or 14 days and temozolomide 75-100 mg m 2 on days 1-5. Drugs were administered orally with cycles repeated every 28 days, for up to six cycles. A total of 32 patients were recruited to the study. Lomeguatrib for 10 days with temozolomide 75 mg m 2 was established as the optimal extended lomeguatrib dosing schedule, with haematological toxicity being dose limiting. There were two partial responses to treatment giving an overall response rate of 6.25%. Extending lomeguatrib administration beyond that of temozolomide requires a reduced dose of the latter agent. Only limited clinical activity was seen, suggesting no advantage for this regimen over conventional temozolomide administration in the treatment of melanoma.

Original languageEnglish
Pages (from-to)1245-1249
Number of pages5
JournalBritish Journal of Cancer
Volume100
Issue number8
DOIs
Publication statusPublished - 21 Apr 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma'. Together they form a unique fingerprint.

Cite this